Regulus Therapeutics (NASDAQ:RGLS) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Get Rating) in a report issued on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently weighed in on RGLS. Canaccord Genuity Group started coverage on shares of Regulus Therapeutics in a report on Tuesday, November 8th. They issued a “buy” rating and a $9.00 price target on the stock. Canaccord Genuity Group began coverage on shares of Regulus Therapeutics in a research report on Monday, November 7th. They issued a “buy” rating and a $9.00 price objective on the stock.

Regulus Therapeutics Stock Up 5.9 %

NASDAQ:RGLS opened at $1.43 on Friday. The company has a fifty day moving average of $1.42 and a 200-day moving average of $1.56. The firm has a market capitalization of $20.92 million, a P/E ratio of -0.65 and a beta of 1.65. Regulus Therapeutics has a twelve month low of $1.08 and a twelve month high of $3.70.

Institutional Investors Weigh In On Regulus Therapeutics

Large investors have recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in Regulus Therapeutics by 108.5% in the 3rd quarter. BlackRock Inc. now owns 45,614 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 23,738 shares in the last quarter. Commonwealth Equity Services LLC increased its position in shares of Regulus Therapeutics by 52.3% during the 3rd quarter. Commonwealth Equity Services LLC now owns 33,500 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 11,500 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Regulus Therapeutics during the 3rd quarter valued at approximately $54,000. Renaissance Technologies LLC grew its position in Regulus Therapeutics by 498.2% in the 1st quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 111,100 shares during the last quarter. Finally, Northern Trust Corp grew its position in Regulus Therapeutics by 42.9% in the 1st quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 50,518 shares during the last quarter. 55.47% of the stock is currently owned by institutional investors.

About Regulus Therapeutics

(Get Rating)

Regulus Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.